Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed
Entrada Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 5, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 655 | 503 | 424 | 534 | - | - |
Market Cap Growth | 7.07% | 18.72% | -20.71% | - | - | - |
Enterprise Value | 220 | 219 | 236 | 610 | - | - |
Last Close Price | 17.77 | 15.09 | 13.52 | 17.12 | - | - |
PE Ratio | 12.01 | -74.60 | -4.47 | -2.10 | - | - |
PS Ratio | 2.93 | 3.90 | - | - | - | - |
PB Ratio | 1.57 | 2.08 | 1.99 | 1.79 | - | - |
P/FCF Ratio | -32.20 | 3.75 | -4.38 | -9.64 | - | - |
P/OCF Ratio | -40.26 | 3.60 | -4.52 | -10.51 | - | - |
EV/Sales Ratio | 1.02 | 1.69 | - | - | - | - |
EV/EBITDA Ratio | 3.59 | -680.70 | -2.48 | -12.19 | - | - |
EV/EBIT Ratio | 3.81 | -69.10 | -2.43 | -11.92 | - | - |
EV/FCF Ratio | -8.99 | 1.63 | -2.44 | -11.00 | - | - |
Debt / Equity Ratio | 0.15 | 0.28 | 0.12 | - | - | - |
Debt / EBITDA Ratio | 0.81 | 4.68 | - | - | - | - |
Debt / FCF Ratio | -3.51 | 0.51 | -0.27 | - | - | - |
Asset Turnover | 0.41 | 0.36 | - | - | - | - |
Quick Ratio | 6.40 | 2.26 | 8.62 | 43.32 | 11.62 | 8.77 |
Current Ratio | 6.59 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
Return on Equity (ROE) | 16.43% | -2.94% | -37.01% | -30.19% | -93.94% | - |
Return on Assets (ROA) | 6.95% | -0.55% | -21.79% | -18.29% | -53.97% | - |
Return on Capital (ROIC) | 9.03% | -0.72% | -22.63% | -18.86% | -59.03% | - |
Earnings Yield | 8.79% | -1.33% | -22.33% | -9.57% | - | - |
FCF Yield | -2.79% | 26.68% | -22.82% | -10.38% | - | - |
Buyback Yield / Dilution | -9.14% | -5.61% | -399.27% | -467.09% | -18.45% | - |
Total Shareholder Return | -9.14% | -5.61% | -399.27% | -467.09% | -18.45% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.